INCLINE VILLAGE, Nev., Jan. 5, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 29th Annual JP Morgan Healthcare Conference in San Francisco at 7:30 a.m. Pacific time.
This presentation will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcast of the presentation, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following each presentation.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
|SOURCE PDL BioPharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved